Literature DB >> 1985117

Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells.

W A Marijt1, W F Veenhof, A Brand, E Goulmy, W E Fibbe, R Willemze, J J van Rood, J H Falkenburg.   

Abstract

Recipient-antidonor alloreactivity before HLA genotypically identical bone marrow transplantation (BMT) between donor-recipient pairs that are negative in the mixed lymphocyte reaction (MLR), the cell-mediated lympholysis (CML) assay, and the lymphocyte crossmatch was not detectable in the majority of cases, using recipient peripheral blood lymphocytes (PBL) collected before BMT as responder cells and donor PBL as stimulator cells. However, when donor bone marrow mononuclear cells (BMMNC) instead of PBL were used as stimulator cells, we could detect donor-specific alloreactivity in 7 of 10 HLA genotypically identical donor-recipient pairs. To demonstrate that this alloreactivity was minor histocompatibility (mH) antigen specific and not directed against HLA class I splits or variants, two cytotoxic T lymphocyte (CTL) lines were tested in further detail against phytohemagglutinin (PHA) blasts from pairs of HLA genotypically identical siblings positive for the HLA class I restriction molecule. Both CTL lines recognized mH antigens, as illustrated by the differential recognition of PHA blasts of one of the two siblings from several pairs. The potential role of these mH antigen-specific CTLs in bone marrow graft rejection was demonstrated by the mH antigen-specific growth inhibition of hematopoietic progenitor cells from the original bone marrow donor and from HLA class I restriction molecule-positive individuals who expressed the mH antigens on their PBL and BMMNC. Our assay can be used in HLA genotypically identical BMT to detect a recipient-antidonor response, directed against cellularly defined mH antigens expressed on donor HPC, BMMNC, and PBL, before transplantation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985117      PMCID: PMC2118770          DOI: 10.1084/jem.173.1.101

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Detection of genetically determined histocompatibility antigen differences between HL-A identical and MLC nonreactive siblings.

Authors:  R Parkman; F S Rosen; J Rappeport; B Camitta; R L Levey; D G Nathan
Journal:  Transplantation       Date:  1976-02       Impact factor: 4.939

2.  The detection of non-HLA antibodies and their possible role in bone marrow graft rejection.

Authors:  F H Claas; J J van Rood; R P Warren; P L Weiden; P J Su; R Storb
Journal:  Transplant Proc       Date:  1979-03       Impact factor: 1.066

3.  Growth in vitro of donor marrow cultured with recipient lymphocytes predicts the fate of marrow grafts in transfused DLA-identical dogs.

Authors:  B J Torok-Storb; R Storb; H J Deeg; T C Graham; C Wise; P L Weiden; J W Adamson
Journal:  Blood       Date:  1979-01       Impact factor: 22.113

4.  Serum inhibitors of in vitro hematopoiesis and graft outcome in bone marrow transplantation for aplastic anemia.

Authors:  J H Fitchen; R P Gale; M J Cline
Journal:  Transplantation       Date:  1980-03       Impact factor: 4.939

5.  Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation.

Authors:  E Kaminski; J Hows; S Man; P Brookes; S Mackinnon; T Hughes; O Avakian; J M Goldman; J R Batchelor
Journal:  Transplantation       Date:  1989-10       Impact factor: 4.939

6.  Immunological studies in patients with aplastic anemia who rejected marrow grafts from HLA-identical sibling donors.

Authors:  R P Warren; R Storb; E D Thomas
Journal:  Transplantation       Date:  1982-11       Impact factor: 4.939

7.  A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease.

Authors:  E Goulmy; J W Gratama; E Blokland; F E Zwaan; J J van Rood
Journal:  Nature       Date:  1983-03-10       Impact factor: 49.962

8.  Prediction of marrow graft rejection by the lymphocyte-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity assays.

Authors:  R P Warren; R Storb; P L Weiden; P J Su; E D Thomas
Journal:  Transplantation       Date:  1980-08       Impact factor: 4.939

9.  Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms.

Authors:  C Bordignon; C A Keever; T N Small; N Flomenberg; B Dupont; R J O'Reilly; N A Kernan
Journal:  Blood       Date:  1989-11-01       Impact factor: 22.113

10.  Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens.

Authors:  P J Voogt; W E Fibbe; W A Marijt; E Goulmy; W F Veenhof; M Hamilton; A Brand; F E Zwann; R Willemze; J J van Rood
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

View more
  7 in total

1.  Tissue distribution and polymorphism of minor histocompatibility antigens involved in GVHR.

Authors:  I Miconnet; V de la Selle; C Tucek; R Huchet; D Bonardelle; M Bruley-Rosset
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

2.  Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.

Authors:  Marie Bleakley; Brith E Otterud; Julia L Richardt; Audrey D Mollerup; Michael Hudecek; Tetsuya Nishida; Colette N Chaney; Edus H Warren; Mark F Leppert; Stanley R Riddell
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

3.  Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells.

Authors:  A A Danen-Van Oorschot; D F Fischer; J M Grimbergen; B Klein; S Zhuang; J H Falkenburg; C Backendorf; P H Quax; A J Van der Eb; M H Noteborn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 4.  Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Authors:  A J Barrett; K Rezvani
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

Review 5.  Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.

Authors:  R Champlin; S Giralt; I Khouri
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.075

6.  Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Authors:  J H Falkenburg; H M Goselink; D van der Harst; S A van Luxemburg-Heijs; Y M Kooy-Winkelaar; L M Faber; J de Kroon; A Brand; W E Fibbe; R Willemze
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

7.  Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.

Authors:  L M Faber; S A van Luxemburg-Heijs; R Willemze; J H Falkenburg
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.